Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association
Gissette Reyes‐Soffer, Henry N. Ginsberg, Lars Berglund, et al.
Arteriosclerosis Thrombosis and Vascular Biology (2021) Vol. 42, Iss. 1
Open Access | Times Cited: 461

Showing 1-25 of 461 citing articles:

Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement
Florian Kronenberg, Samia Mora, Erik S.G. Stroes, et al.
European Heart Journal (2022) Vol. 43, Iss. 39, pp. 3925-3946
Open Access | Times Cited: 660
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease
Michelle L. O’Donoghue, Robert S. Rosenson, Bariş Gencer, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 20, pp. 1855-1864
Open Access | Times Cited: 289
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue
Laura Connelly‐Smith, Caroline R. Alquist, Nicole A. Aqui, et al.
Journal of Clinical Apheresis (2023) Vol. 38, Iss. 2, pp. 77-278
Closed Access | Times Cited: 271
Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association
Sadiya S. Khan, Josef Coresh, Michael Pencina, et al.
Circulation (2023) Vol. 148, Iss. 24, pp. 1982-2004
Closed Access | Times Cited: 175
Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation
Stephen J. Nicholls, Steven E. Nissen, Cynthia Griggs Fleming, et al.
JAMA (2023) Vol. 330, Iss. 11, pp. 1042-1042
Open Access | Times Cited: 101
From target discovery to clinical drug development with human genetics
Katerina Trajanoska, Claude Bhérer, Daniel Taliun, et al.
Nature (2023) Vol. 620, Iss. 7975, pp. 737-745
Closed Access | Times Cited: 97
Non-genetic influences on lipoprotein(a) concentrations
Byambaa Enkhmaa, Lars Berglund
Atherosclerosis (2022) Vol. 349, pp. 53-62
Open Access | Times Cited: 85
Lipoprotein(a) and cardiovascular and valvular diseases: A genetic epidemiological perspective
Benoît J. Arsenault, Pia R. Kamstrup
Atherosclerosis (2022) Vol. 349, pp. 7-16
Closed Access | Times Cited: 82
Ten things to know about ten cardiovascular disease risk factors – 2022
Harold Bays, Anandita Agarwala, Charles German, et al.
American Journal of Preventive Cardiology (2022) Vol. 10, pp. 100342-100342
Open Access | Times Cited: 79
A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice
Marlys L. Koschinsky, Archna Bajaj, Michael B. Boffa, et al.
Journal of clinical lipidology (2024) Vol. 18, Iss. 3, pp. e308-e319
Closed Access | Times Cited: 74
Lipoprotein(a) Is Markedly More Atherogenic Than LDL
Elias Björnson, Martin Adiels, Marja‐Riitta Taskinen, et al.
Journal of the American College of Cardiology (2024) Vol. 83, Iss. 3, pp. 385-395
Open Access | Times Cited: 71
Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association
Carol F. Kirkpatrick, Geeta Sikand, Kristina Petersen, et al.
Journal of clinical lipidology (2023) Vol. 17, Iss. 4, pp. 428-451
Open Access | Times Cited: 47
Clinical Trial Design for Lipoprotein(a)-Lowering Therapies
Waqas Malick, Sascha N. Goonewardena, Wolfgang Köenig, et al.
Journal of the American College of Cardiology (2023) Vol. 81, Iss. 16, pp. 1633-1645
Open Access | Times Cited: 46
Lipoprotein(a) Testing Trends in a Large Academic Health System in the United States
Harpreet Bhatia, Samantha Hurst, Paresh Desai, et al.
Journal of the American Heart Association (2023) Vol. 12, Iss. 18
Open Access | Times Cited: 45
Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives
Pierandrea Vinci, Filippo Giorgio Di Girolamo, Emiliano Panizon, et al.
International Journal of Environmental Research and Public Health (2023) Vol. 20, Iss. 18, pp. 6721-6721
Open Access | Times Cited: 41
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Daniel Tobias Michaeli, Julia Caroline Michaeli, Sebastian Albers, et al.
American Journal of Cardiovascular Drugs (2023) Vol. 23, Iss. 5, pp. 477-495
Open Access | Times Cited: 40
Atherosclerotic plaque stabilization and regression: a review of clinical evidence
Ashish Sarraju, Steven E. Nissen
Nature Reviews Cardiology (2024) Vol. 21, Iss. 7, pp. 487-497
Closed Access | Times Cited: 31
Bayesian estimation of gene constraint from an evolutionary model with gene features
Tony Zeng, Jeffrey P. Spence, Hakhamanesh Mostafavi, et al.
Nature Genetics (2024) Vol. 56, Iss. 8, pp. 1632-1643
Open Access | Times Cited: 26
Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels
Bożena Sosnowska, Janina Stępińska, Przemysław Mitkowski, et al.
Archives of Medical Science (2024) Vol. 20, Iss. 1, pp. 8-27
Open Access | Times Cited: 18
Lipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic Pooled Prospective Cohort
Nathan D. Wong, Wenjun Fan, Xingdi Hu, et al.
Journal of the American College of Cardiology (2024) Vol. 83, Iss. 16, pp. 1511-1525
Open Access | Times Cited: 18
Lipoprotein(a) and cardiovascular disease
Børge G. Nordestgaard, Anne Langsted
The Lancet (2024)
Closed Access | Times Cited: 18
High lipoprotein(a): Actionable strategies for risk assessment and mitigation
Gissette Reyes‐Soffer, Calvin Yeang, Erin D. Michos, et al.
American Journal of Preventive Cardiology (2024) Vol. 18, pp. 100651-100651
Open Access | Times Cited: 17
ApoB100 and Atherosclerosis: What’s New in the 21st Century?
Dimitris Kounatidis, Natalia G. Vallianou, Aikaterini Poulaki, et al.
Metabolites (2024) Vol. 14, Iss. 2, pp. 123-123
Open Access | Times Cited: 15
Apolipoprotein B-containing lipoproteins in atherogenesis
Jan Borén, Chris J. Packard, Christoph J. Binder
Nature Reviews Cardiology (2025)
Closed Access | Times Cited: 2
Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)
Michelle L. O’Donoghue, J. Antonio G. López, Beat Knüsel, et al.
American Heart Journal (2022) Vol. 251, pp. 61-69
Open Access | Times Cited: 66
Page 1 - Next Page

Scroll to top